Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation

Paola Minetto, MD PhD, Anna Candoni, Fabio Guolo, MD, Marino Clavio, MD, Maria Elena Zannier, MD, Maurizio Miglino, PhD, Maria Vittoria Dubbini, MD, Anna Sicuranza, PhD, Sara Ciofini, Elisabetta Tedone, Nicoletta Colombo, PhD, Girolamo Pugliese, Filippo Ballerini, MD, Michele Cea, Monica Bocchia, Renato Fanin, MD, Roberto Massimo Lemoli, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142887

Published: 2020

Journal Articles

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Blood (2019) 134 (Supplement_1): 3828.

https://doi.org/10.1182/blood-2019-131303

Published: 2019

Journal Articles

A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML

Fabio Guolo, MD, Paola Minetto, MD, Annalisa Kunkl, MD, Elisabetta Tedone, Marino Clavio, MD, Maurizio Miglino, PhD, Fabrizio Caviglia, Nicoletta Colombo, PhD, Antonia Cagnetta, MD, Michele Cea, MD, Filippo Ballerini, MD, Jean Louis Ravetti, MD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2018) 132 (Supplement 1): 5243.

https://doi.org/10.1182/blood-2018-99-118984

Published: 2018

Journal Articles

Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients

Fabio Guolo, MD, Paola Minetto, MD, Marino Clavio, MD, Nicoletta Colombo, PhD, Annalisa Kunkl, MD, Enrico Carminati, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Emanuele Angelucci, Roberto M Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 3316.

https://doi.org/10.1182/blood.V130.Suppl_1.3316.3316

Published: 2017

Journal Articles

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Simona Matarese, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Antonia Cagnetta, MD, Michele Cea, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 5047.

https://doi.org/10.1182/blood.V130.Suppl_1.5047.5047

Published: 2017

Journal Articles

Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It's Time for MRD-Driven Therapy

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Filippo Ballerini, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Giordana Pastori, MD, Simona Matarrese, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Andrea Bacigalupo, MD, Roberto Massimo Lemoli, MD, Maurizio Miglino, PhD, Marco Gobbi, MD

Blood (2016) 128 (22): 2895.

https://doi.org/10.1182/blood.V128.22.2895.2895

Published: 2016

Journal Articles

Combining Flow Cytometry and Molecular Assessment Improves the Prognostic Value of Pre-Transplant Minimal Residual Disease in Acute Myeloid Leukemia

Fabio Guolo, MD, Paola Minetto, MD, Federica Galaverna, MD, Daniela Guardo, MD, Nicoletta Colombo, PhD, Annalisa Kunkl, MD, Marino Clavio, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD, Andrea Bacigalupo, MD

Blood (2016) 128 (22): 521.

https://doi.org/10.1182/blood.V128.22.521.521

Published: 2016

Journal Articles

SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia

Michele Cea, MD, Antonia Cagnetta, MD, Debora Soncini, PhD, Paola Minetto, MD, Davide Lovera, MD, Fabio Guolo, MD, Nicoletta Colombo, PhD, Filippo Ballerini, MD, Marino Clavio, MD, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto M Lemoli, MD

Blood (2016) 128 (22): 5222.

https://doi.org/10.1182/blood.V128.22.5222.5222

Published: 2016

Journal Articles

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Michele Cea, MD, Antonia Cagnetta, MD, Davide Lovera, MD, Raffaella Grasso, PhD, Nicoletta Colombo, PhD, Micaela Bergamaschi, MD, Sara Aquino, MD, Fabio Guolo, MD, Paola Minetto, MD, Filippo Ballerini, MD, Letizia Canepa, MD, Sophia Adamia, PhD, Alessio Nencioni, Ivana Pierri, MD, Marino Clavio, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2015) 126 (23): 1375.

https://doi.org/10.1182/blood.V126.23.1375.1375

Published: 2015

Journal Articles

High Predictive Value of Pre Transplant Minimal Residual Disease Assessment By Combining WT1 Expression and Flow Cytometry in Acute Myeloid Leukemia

Fabio Guolo, MD, Federica Galaverna, MD, Paola Minetto, MD, Livia Giannoni, MD, Chiara Ghiggi, PhD, Marino Clavio, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Nicoletta Colombo, PhD, Raffaella Grasso, PhD, Maurizio Miglino, PhD, Adalberto Ibatici, MD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD, Andrea Bacigalupo, MD

Blood (2015) 126 (23): 2029.

https://doi.org/10.1182/blood.V126.23.2029.2029

Published: 2015

Journal Articles

Allogeneic Transplanst for ACUTE Myeloid Leukemia: Cut Off Levels of WT1 Expression in 207 Patients and Pre-Emptive Therapy of Relapse

Carmen Di Grazia, MD, Simona Geroldi, Raffaella Grasso, PhD, Maurizio Miglino, PhD, Nicoletta Colombo, PhD, Elisabetta Tedone, Silvia Luchetti, Teresa Lamparelli, Francesca Gualandi, MD, Adalberto Ibatici, MD, Stefania Bregante, Maria Teresa van Lint, Anna Maria Raiola, Alida Dominietto, MD, Riccardo Varaldo, Federica Galaverna, Anna Ghiso, Andrea Bacigalupo, MD

Blood (2015) 126 (23): 1866.

https://doi.org/10.1182/blood.V126.23.1866.1866

Published: 2015

Journal Articles

High Prognostic Value of a 3-Genes Molecular Score in Non-High Risk Acute Promyelocytic Leukemia Treated with AIDA 2000 Protocol: A Retrospective Study from a Regional Register

Guardo Daniela, MD, Fabio Guolo, MD, Paola Minetto, MD, Marino Clavio, MD, Livia Giannoni, MD, Elisa Coviello, MD, Giordana Pastori, MD, Giulia Rivoli, MD, Filippo Ballerini, MD, Nicoletta Colombo, PhD, Raffaella Grasso, PhD, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2015) 126 (23): 2601.

https://doi.org/10.1182/blood.V126.23.2601.2601

Published: 2015

Journal Articles

Fludarabine, Cytarabine, Daunoxome Plus Dasatinib Has High Efficacy with an Acceptable Toxicity Profile As Either Consolidation or Salvage Regimen in Adult Philadelphia Positive Acute Lymphoblastic Leukemia Patients

Giordana Pastori, MD, Fabio Guolo, MD, Daniela Guardo, MD, Paola Minetto, MD, Marino Clavio, MD, Maurizio Miglino, PhD, Livia Giannoni, MD, Elisa Coviello, MD, Filippo Ballerini, MD, Federica Galaverna, MD, Annalisa Kunkl, PhD, Nicoletta Colombo, PhD, Raffaella Grasso, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2015) 126 (23): 4908.

https://doi.org/10.1182/blood.V126.23.4908.4908

Published: 2015

Journal Articles

Combined Assessment of WT1 and BAALC Expression Levels Improves Risk Stratification in Myelodysplastic Syndromes

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Laura Mitscheunig, Raffaella Grasso, PhD, Nicoletta Colombo, PhD, Enrico De Astis, MD, Daniele Avenoso, MD, Livia Giannoni, MD, Giordana Pastori, MD, Lisette Del Corso, MD, Enrico Balleari, MD, Filippo Ballerini, MD, Roberto Lemoli, MD, Marco Gobbi, MD, Maurizio Miglino, PhD

Blood (2014) 124 (21): 5603.

https://doi.org/10.1182/blood.V124.21.5603.5603

Published: 2014

Journal Articles

Fludarabine, cytarabine and Idarubicin (FLAI-5) with or without Gemtuzumab Ozogamicin Is an Effective and Well Tolerated Regimen for Younger AML Patients: Real Life Data from a Single Center Register

Fabio Guolo, MD, Paola Minetto, MD, Giordana Pastori, MD, Livia Giannoni, MD, Nicoletta Colombo, PhD, Raffaella Grasso, PhD, Francesco Trovato, MD, Marcella Bado, MD, Filippo Ballerini, MD, Marino Clavio, MD, Barbara Rebesco, MD, Maurizio Miglino, PhD, Andrea Bacigalupo, MD, Marco Gobbi, MD, Roberto Lemoli, MD

Blood (2014) 124 (21): 2266.

https://doi.org/10.1182/blood.V124.21.2266.2266

Published: 2014

Journal Articles

Prognostic Value of Minimal Residual Disease Assessed By WT1 Expression Level and Flow Cytometry in Acute Myeloid Leukemia Patients Undergoing Allogeneic Marrow Transplantation

Livia Giannoni, MD, Fabio Guolo, MD, Paola Minetto, MD, Federica Galaverna, MD, Chiara Ghiggi, MD, Marino Clavio, MD, Samuele Bagnasco, MD, Carmen Di Grazia, MD, Raffaella Grasso, PhD, Nicoletta Colombo, PhD, Daniele Avenoso, MD, Giordana Pastori, MD, Filippo Ballerini, MD, Annalisa Kunkl, PhD, Maurizio Miglino, PhD, Roberto Lemoli, MD, Marco Gobbi, MD, Andrea Bacigalupo, MD

Blood (2014) 124 (21): 1027.

https://doi.org/10.1182/blood.V124.21.1027.1027

Published: 2014

Journal Articles

Detection of an Unbalanced Ratio Between WT1 Isoforms in Acute Myeloid Leukemia and Its Correlation with Molecular Abnormalities.

Chiara Calabrese, PhD, Gian Matteo Pica, MD, Enrico Bracco, PhD, Anna Serra, PhD, Francesca Carnuccio, PhD, Sonia Carturan, PhD, Valentina Campia, PhD, Chiara Ghiggi, PhD, Fabio Guolo, PhD, Angelo Michele Carella, MD, Nicoletta Colombo, PhD, Raffaella Grasso, PhD, Maurizio Miglino, PhD, Francesco Frassoni, Giuseppe Saglio, MD, Daniela Cilloni, MD

Blood (2012) 120 (21): 2500.

https://doi.org/10.1182/blood.V120.21.2500.2500

Published: 2012

NARROW

Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML

Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It's Time for MRD-Driven Therapy

Combining Flow Cytometry and Molecular Assessment Improves the Prognostic Value of Pre-Transplant Minimal Residual Disease in Acute Myeloid Leukemia

SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

High Predictive Value of Pre Transplant Minimal Residual Disease Assessment By Combining WT1 Expression and Flow Cytometry in Acute Myeloid Leukemia

Allogeneic Transplanst for ACUTE Myeloid Leukemia: Cut Off Levels of WT1 Expression in 207 Patients and Pre-Emptive Therapy of Relapse

High Prognostic Value of a 3-Genes Molecular Score in Non-High Risk Acute Promyelocytic Leukemia Treated with AIDA 2000 Protocol: A Retrospective Study from a Regional Register

Fludarabine, Cytarabine, Daunoxome Plus Dasatinib Has High Efficacy with an Acceptable Toxicity Profile As Either Consolidation or Salvage Regimen in Adult Philadelphia Positive Acute Lymphoblastic Leukemia Patients

Combined Assessment of WT1 and BAALC Expression Levels Improves Risk Stratification in Myelodysplastic Syndromes

Fludarabine, cytarabine and Idarubicin (FLAI-5) with or without Gemtuzumab Ozogamicin Is an Effective and Well Tolerated Regimen for Younger AML Patients: Real Life Data from a Single Center Register

Prognostic Value of Minimal Residual Disease Assessed By WT1 Expression Level and Flow Cytometry in Acute Myeloid Leukemia Patients Undergoing Allogeneic Marrow Transplantation

Detection of an Unbalanced Ratio Between WT1 Isoforms in Acute Myeloid Leukemia and Its Correlation with Molecular Abnormalities.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only